Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Neurocrine (NBIX – Research Report) and keeping the price target at $180.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mohit Bansal has given his Buy rating due to a combination of factors including the stabilization prospects for Neurocrine’s Ingrezza. Despite the current weak guidance driven by trends from the second half of 2024, there is an expectation for stabilization in the second half of 2025. This presents what Bansal views as a buying opportunity despite recent challenges.
Additionally, the competitive landscape with Austedo is expected to normalize, as the full range of Austedo XR doses has only recently become available, and Teva has expanded its sales force. While a slight decline in Ingrezza’s market share is anticipated, overall market growth remains robust. Even with a moderate decrease in market share, there are expectations for significant sales growth in the coming year, providing further upside potential to the current guidance.
In another report released on February 11, Morgan Stanley also maintained a Buy rating on the stock with a $185.00 price target.
NBIX’s price has also changed moderately for the past six months – from $150.700 to $116.870, which is a -22.45% drop .